A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf.
Development of nitroimidazopyrans and nitroimidaoxazoles for tuberculosis chemotherapy
2014
El Mednifico Journal
Preserved Fulltext
The conventional approach to antitubercular drug development requires introduction of novel molecules for the treatment of resistant mycobacterium strains. The nitroimidazopyrans, nitroimidaoxazoles and other analogs are being studied as antitubercular agents and their characteristics form the basis of this review. These new tuberculosis treatments shorten the duration of treatment and/or reduce the number of doses, improve the coverage of MDR-TB/XDR-TB and are more effective in treatment of latent TB infection. (El Med J 2:4; 2014)
doi:10.18035/emj.v2i4.253
fatcat:6fwas4vvyvbrxghiizlw5n6vdm